My research combines the phenotypic/clinical analysis with multi-OMICs approaches to understand the fundamental question of how over-nutritional signals alter chromatin remodelling to promote metabolic disease development.
We have so far analyzed different patient samples in the transcriptomic, cistromic and epigenomic levels and identified a group of interesting candidates involved in species-conserved and disease-relevant regulation of glucose and lipid metabolism. Of particular interest is the transcription factor coregulator GPS2, the dysregulation of which is associated with de-repressed inflammation and impaired lipid oxidation pathways, leading to type 2 diabetes and liver disease progression.
The ongoing research activity involves further investigation of the coregulator-based mechanisms in the genomic and epigenomic level in various disease contexts. Understanding such pathways is crucial for better deciphering disease mechanisms which is ultimately required for identifying novel targets with diagnostic and intervention potential.
- Main supervisor of 1 ongoing PhD student
- Cosupervisor of 1 ongoing PhD student and 2 completed PhD students
- Project supervisor of 3 bachelor students and 1 Master student
- Evaluation of 4 Master theses
- Half-time committee of 2 PhD students
- Mentor of 2 PhD students
- More than 120 teaching hours in Bachelor, Master and PhD courses
- Professional university pedagogy training (equivalent to more than 5 weeks)
- 2022 to present: Associate professor/docent at the Department of Biosciences and Nutrition, Karolinska Institute, Flemingsberg.
- 2018 to 2021: Assistant professor at the Department of Biosciences and Nutrition, Karolinska Institute, Fleminsberg.
- 2012 to 2017: Postdoctoral Study at the Department of Biosciences and Nutrition, Karolinska Institute, Fleminsberg.
- 2012: PhD in Medical Sciences, Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong.
Akademiska priser och utmärkelser
- The Rolf Luft Grant for Instrumentation 2022
- SRP diabetes 2022
- KI faculty-funded senior researcher 2021
- EFSD / Novo Nordisk Future Leaders Award 2021
- Swedish research council (Vetenskapsrådet)
- Novo Nordisk Foundation
- KI Doctoral funding
- Åke Wibergs Stiftelse
- Diabetes Wellness Sverige Foundation
- EFSD / Lilly research fellowship
- KI foundation
Commission of trust:
- Editorial board: Frontiers in Endocrinology 2021-.
- Guest editor: Frontiers in Endocrinology 2020.
- Steering Committee: lipoprotein research networks in KI south campus (supported by CIMED).
- Grant review task for: French National Research Agency (ANR)
- Grant review panel: Cancerfonden, KID
- Invited reviewer in: Nature Communications, eLife, JBC, FASEB J, Diabetologia, Diabetes, obesity and metabolism, PLoS One, Journal of cellular and molecular medicine, etc.
- Poster assesment committee: Epigenomics, nuclear receptor and diseases summer school. Spetses, 2019.
- Poster assesment committee: 7th Endometrial SRP Diabetes Joint Retreat. Stockholm, 2017.
- Poster assesment committee: Epigenomics, nuclear receptor and diseases summer school. Spetses, 2017.
1) Huang, Z., Efthymiadou, A., Liang, N., Fan RR# (co-corresponding author)., Eckardt Treuter#. Antagonistic action of GPS2 and KDM1A at enhancers governs alternative macrophage activation by interleukin 4. Nucleic Acids Research 2023. gkac1230, https://doi.org/10.1093/nar/gkac1230.
2) Huang, Z., Liang, N., Goni, S., Damdimopoulos, A., Wang, C., Ballaire, R., Jager, J., Niskanen, H., Jakobsson., Han, H., Bracken, A., Aouadi, M., Venteclef, N., Kaikkonen, M., Fan, RR# (co-corresponding author)., Treuter, E#. The corepressors GPS2 and SMRT control enhancer and silencer remodelling linked to eRNA transcription during inflammatory activation of macrophages. Molecular Cell 2021 (Featured article) 2021. 81(5):953-968.e9.
3) Kang, ZF., Fan, RR. PPARα and NCOR / SMRT corepressor network in liver metabolic regulation. FASEB J 2020. doi: 10.1096/fj.202000055RR.
4) Liang, N., Damdimopoulos, A., Goñi, S., Huang, ZQ., Vedin, L., Jakobsson, T., Giudici, M., Ahmed, O., Pedrelli, M., Barilla, S., Alzaid, F., Mendoza, A., Schröder, T., Kuiper, R., Parini, P., Hollenberg, A., Lefebvre, P., Francque, S., Gaal, LV., Staels, B., Venteclef, N., Treuter, E#., and Fan, RR#. Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPARα. Nature Communications 2019. 10:1684.
5) Huang, ZQ., Liang, N., Damdimopoulos, T., Fan, RR# (co-corresponding author) and Treuter, E#. G-protein pathway suppressor 2 links inflammation and cholesterol efflux by controlling lipopolysaccharide-induced ATP-binding cassette transporter A1 expression in macrophages. FASEB J (Cover story) 2018. doi: 10.1096/fj.201801123R.
6) Fan, R.R., Toubal, A., Goñi, S., Drareni, K., Huang, ZQ., Alzaid, F., Ballaire, R., Ancel,P., Liang, N., Damdimopoulos, A., Hainault, I., Soprani, A., Wisnewsky, JA., Foufelle, F., Lawrence, T., Gautier, JF., Venteclef, N & Treuter, E. Loss of the corepressor GPS2 sensitizes macrophage activation upon metabolic stress induced by obesity and type 2 diabetes. Nature Medicine 2016. doi:10.1038/nm.4114.